Company: PHAT
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034183
Chunk: 261

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 1B
Chunk 261
---
    155,890

    Cash and cash equivalents and restricted cash – end of period
     
    $
    300,125

    $
    384,256

    Supplemental disclosure of cash flow information

    Interest paid
     
    $
    17,293

    $
    11,133

    Supplemental disclosure of noncash investing and financing activities:

    Property and equipment purchases included in accounts payable and accrued expenses
     
    $
    8

    $
    18

    Final interest payment fee
     
    $
    1,800

    $
    2,200

    Settlement of ESPP liability in common stock
     
    $
    2,401

    $
    1,417

    Settlement of 401(k) liability in common stock
     
    $
    3,683

    $
    1,612

See accompanying notes.

F-7

PHATHOM PHARMACEUTICALS, INC.

Notes to Financial Statements

1. Organization, Basis of Presentation and Summary of Significant Accounting Policies Organization and Basis of Presentation Phathom Pharmaceuticals, Inc., or the Company or Phathom, was incorporated in the state of Delaware in January 2018. The Company is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. The Company’s financial statements are prepared in accordance with U.S. generally accepted accounting principles, or GAAP.   On October 27, 2023, the U.S. Food and Drug Administration, or FDA, approved the prior approval supplements to the Company's new drug applications, or NDAs, for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK. Additionally, on November 1, 2023, the FDA approved the Company's NDA for VOQUEZNA tablets. The Company initiated commercial launch for VOQUEZNA for both the Erosive GERD and H. pylori indications, and VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for treatment of H. pylori infection in the fourth quarter of 2023. Additionally, on July 17, 2024, the FDA approved VOQUEZNA 10 mg tablets for the relief of heartburn associated with Non-Erosive GERD.Liquidity and Capital Resources From inception to December 31, 2024, the Company has devoted substantially all of its efforts to organizing and staffing the